Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort
DOI:
https://doi.org/10.2340/actadv.v101.566Keywords:
psoriasis, drug survival, treatments, biologics, apremilastAbstract
Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic disease-modifying antirheumatic drugs (sDMARDs). The aim of this study was to determine whether the increasing number of available systemic treatments for psoriasis affects drug survival over time. Patients were selected from the PsoBioTeq cohort, a French prospective observational cohort enrolling patients with moderate to severe psoriasis. All patients initiating a first bDMARD or sDMARD were included. The primary outcome was comparison of drug survival over time. A multivariate Cox proportional hazard ratio model was computed. A total of 1,866 patients were included; 739 females (39%), median age 47 years. In the multivariate Cox model, no association was found between the calendar year of initiation and drug survival (hazard ratio) overlapping from 0.80 (0.42–1.52) to 1.17 (0.64–2.17), p = 0.633). In conclusion, drug survival in psoriasis is not affected by the year of initiation.
Downloads
References
Grodner C, Sbidian E, Weill A, Mezzarobba M. Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database. J Eur Acad Dermatol Venereol 2021; 35: 411-416.
https://doi.org/10.1111/jdv.16566 DOI: https://doi.org/10.1111/jdv.16566
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM, Identification and management of psoriasis and associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
https://doi.org/10.1038/jid.2012.339 DOI: https://doi.org/10.1038/jid.2012.339
Sbidian E, Le Cleach L, Trinquart L, Do G, Hughes C, Naldi L, et al. Systemic pharmacological treatments for chronic plaque psoriasis. Cochrane Skin Group, editor. Cochrane Database Syst Rev 2015 Feb 16 [cited 2020 Nov 1]; Available from: http://doi.wiley.com/10.1002/14651858.CD011535.
https://doi.org/10.1002/14651858.CD011535 DOI: https://doi.org/10.1002/14651858.CD011535
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: CD011535.
https://doi.org/10.1002/14651858.CD011535.pub3 DOI: https://doi.org/10.1002/14651858.CD011535.pub3
Lin P-T, Wang S-H, Chi C-C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep 2018; 8: 16068.
https://doi.org/10.1038/s41598-018-34293-y DOI: https://doi.org/10.1038/s41598-018-34293-y
Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135: 2632-4260.
https://doi.org/10.1038/jid.2015.208 DOI: https://doi.org/10.1038/jid.2015.208
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol 2020; 183: 294-302.
https://doi.org/10.1111/bjd.18981 DOI: https://doi.org/10.1111/bjd.18981
Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García F-J, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol 2016; 30: 1942-1950.
Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019; 180: 86-93.
https://doi.org/10.1111/bjd.16809 DOI: https://doi.org/10.1111/bjd.16809
Shalom G, Cohen AD, Feldhamer I, Comaneshter D, Freud T, Pavlovsky L. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J Eur Acad Dermatol Venereol 2020; 34: 1524-1528.
https://doi.org/10.1111/jdv.16205 DOI: https://doi.org/10.1111/jdv.16205
Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, Beylot-Barry M, Bachelez H, Beneton N, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol 2020; 34: 293-300.
https://doi.org/10.1111/jdv.15878 DOI: https://doi.org/10.1111/jdv.15878
Sbidian E, Giboin C, Bachelez H, Paul C, Beylot-Barry M, Dupuy A, et al. Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the PsoBioTeq cohort. J Eur Acad Dermatol Venereol 2017; 31: 2046-2054.
https://doi.org/10.1111/jdv.14406 DOI: https://doi.org/10.1111/jdv.14406
Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, et al. Biologic drug survival rates in the era of anti-Il-17 antibodies: a time period-adjusted registry analysis. Br J Dermatol 2021; 184: 1094-1105.
https://doi.org/10.1111/bjd.19701 DOI: https://doi.org/10.1111/bjd.19701
Phan C, Beauchet A, Burztejn A-C, Severino-Freire M, Barbarot S, Girard C, et al. Biological treatments for paediatric psoriasis: a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1984-1992.
https://doi.org/10.1111/jdv.15579 DOI: https://doi.org/10.1111/jdv.15579
Sbidian E, Billionnet C, Weill A, Maura G, Mezzarobba M. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database. Br J Dermatol 2020; 182: 690-697.
https://doi.org/10.1111/bjd.18047 DOI: https://doi.org/10.1111/bjd.18047
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49.
https://doi.org/10.1016/j.jaad.2015.03.049 DOI: https://doi.org/10.1016/j.jaad.2015.03.049
Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2014; 28: 907-914.
https://doi.org/10.1111/jdv.12208 DOI: https://doi.org/10.1111/jdv.12208
Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.
https://doi.org/10.1111/bjd.16102 DOI: https://doi.org/10.1111/bjd.16102
Additional Files
Published
How to Cite
License
Copyright (c) 2021 Thomas Bettuzzi, Hervé Bachelez, Marie Beylot-Barry, Hugo Arlégui, Carle Paul, Manuelle Viguier, Emmanuel Mahé, Nathalie Beneton, Denis Jullien, Marie-Aleth Richard, Pascal Joly, Florence Tubach, Alain Dupuy, Emilie Sbidian, Olivier Chosidow, and the PsoBioTeq study group
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
